2,3,5-三氟苯乙酸 | 132992-28-0

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯乙酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3,5-三氟苯乙酸
• 中文别名: 2,3,5-三氟苯醋酸
• 英文名称: 2,3,5-trifluorophenylacetic acid
• 英文别名: 2-(2,3,5-trifluorophenyl)acetic acid
• CAS: 132992-28-0
• 化学式: C₈H₅F₃O₂
• 分子量: 190.122
• InChiKey: HHVKNKDKNBABCU-UHFFFAOYSA-N

物化性质

• 沸点：
  246.3±35.0 °C(Predicted)
• 密度：
  1.468±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2,3,5-三氟苯乙酸 在 盐酸 、 N,N-二甲基丙烯基脲 、 cerium(III) chloride 、 sodium peroxoborate tetrahydrate 、 磷酸吡哆醛 、 1-羟基苯并三唑 、 caesium carbonate 、 对甲苯磺酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 异丙胺 、 三乙胺 、 N,N'-羰基二咪唑 、 lithium tert-butoxide 作用下， 以 四氢呋喃 、 醋酸异丙酯 、 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 81.5h， 生成 (S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,5-trifluorophenyl)piperidin-3-yl)-2’-oxo-1‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3‘-pyrrolo [2,3-b]pyridine]-3-carboxamide
  参考文献：
  名称：

  [EN] PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS
  [FR] PROCÉDÉ DE FABRICATION D'ANTAGONISTES DE RÉCEPTEURS DU CGRP

  摘要：

  该披露涵盖了一种用于制备哌啶酮羧酰胺茚和氮杂茚衍生物的新型过程，与以往的合成方法相比，该过程步骤更少，产率更高。这些化合物是CGRP受体拮抗剂，可用于治疗偏头痛。酰胺键形成的条件包括例如将化合物B（盐断裂后）和C与酰胺偶联试剂以及可选的添加剂和酸和/或碱在非反应性溶剂中反应。

  公开号：

  WO2013169348A1

文献信息

• New Synthesis of 1,3-Dihydro-1,4-benzodiazepin-2(2<i>H</i>)-ones and 3-Amino-1,3-dihydro-1,4-benzodiazepin-2(2<i>H</i>)-ones:  Pd-Catalyzed Cross-Coupling of Imidoyl Chlorides with Organoboronic Acids
  作者：Alan Nadin、José M. Sánchez López、Andrew P. Owens、Dean M. Howells、Adam C. Talbot、Timothy Harrison

  DOI：10.1021/jo026860a

  日期：2003.4.1

  A new approach to the synthesis of 1,4-benzodiazepines and 3-amino-1,4-benzodiazepines, which employs the Pd-catalyzed cross-coupling reaction of an imidoyl chloride with an organometallic reagent as the key step, is described. A five-step synthesis of a key intermediate is described and it is shown that in only four further steps (three couplings and a TFA-mediated BOC-deprotection) a wide variety

  描述了一种合成1,4-苯并二氮杂和3-氨基-1,4-苯并二氮杂的新方法，该方法采用Pd催化的酰亚胺基氯与有机金属试剂的交叉偶联反应作为关键步骤。描述了关键中间体的五步合成方法，结果表明，仅在另外四个步骤中（三个偶联和TFA介导的BOC脱保护），各种N1，C3-氨基，C5-碳，或可以合成氮取代的1，4-苯并二氮杂s。
• [EN] PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS<br/>[FR] PROCÉDÉ DE FABRICATION D'ANTAGONISTES DE RÉCEPTEURS DU CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2013169348A1

  公开（公告）日：2013-11-14

  The disclosure encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, having less steps and improved yields as compared to previous synthetic methods for making these compounds, which are CGRP receptor antagonists, useful for the treatment of migrane. Conditions for an amide bond formation between an acid and amine include for example reacting the compounds of Formulae B (after salt break) and C with an amide coupling reagent and optionally an additive and an acid and/or a base in a non-reactive solvent.

  该披露涵盖了一种用于制备哌啶酮羧酰胺茚和氮杂茚衍生物的新型过程，与以往的合成方法相比，该过程步骤更少，产率更高。这些化合物是CGRP受体拮抗剂，可用于治疗偏头痛。酰胺键形成的条件包括例如将化合物B（盐断裂后）和C与酰胺偶联试剂以及可选的添加剂和酸和/或碱在非反应性溶剂中反应。
• ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS
  申请人：OSRAM OLED GmbH

  公开号：US20180277778A1

  公开（公告）日：2018-09-27

  The invention relates to an organic electronic component ( 100 ) comprising at least one charge generation layer ( 5 ) which has an organically p-doped region ( 5 a ) that contains a zinc complex as a p-dopant, said zinc complex in turn containing at least one ligand L of the following structure: formula (I) wherein R1 and R2 can be oxygen, sulphur, selenium, NH or NR4 independently from one another, wherein R4 is selected from the group containing alkyl or aryl and which can be bonded to R3; and wherein R3 is selected from the group containing alkyl, long-chain alkyl, cycloalkyl, halogen alkyl, at least partially halogenated long-chain alkyl, halogen cycloalkyl, aryl, arylene, halogen aryl, heteroaryl, heteroarylene, heterocyclic alkylene, heterocycloalkyl, halogen heteroaryl, alkenyl, halogen alkenyl, alkynyl, halogen alkynyl, ketoaryl, halogen ketoaryl, ketoheteroaryl, ketoalkyl, halogen ketoalkyl, ketoalkenyl, halogen ketoalkenyl, halogen alkyl aryl, and halogen alkyl heteroaryl, wherein, for suitable groups, one or a number of non-adjacent CH2 groups can be replaced by —O—, —S—, —NH—, —NR ∘∘∘ —, —SiR ∘ R ∘∘ —, —CO—, —COO—, —COR ∘ OR ∘∘ —, —OCO—, —OCO—O—, —SO2-, —S—CO—, —CO—S—, —O—CS—, —CS—O—, —CY1=CY2 or —C≡C— independently from one another, and in such a way that O and/or S atoms are not directly bonded to one another, and are replaced optionally with aryl- or heteroaryl preferably containing between 1 and 30 C atoms (terminal CH3 groups are understood to be CH2 groups in the sense of CH2-H). The invention further relates to the use of a zinc complex as a p-dopant in charge generation layers.

  本发明涉及一种有机电子元件（100），包括至少一个具有有机p-掺杂区域（5a）的电荷生成层（5），该区域含有锌络合物作为p-掺杂剂，所述锌络合物又包含至少一个具有以下结构的配体L：式（I），其中R1和R2可以分别独立地为氧、硫、硒、NH或NR4，其中R4选自含有烷基或芳基的基团，可以与R3结合；R3选自含有烷基、长链烷基、环烷基、卤代烷基、至少部分卤代长链烷基、卤代环烷基、芳基、芳烯基、卤代芳基、杂环芳基、杂环芳烯基、杂环烷基、卤代杂环芳基、烯基、卤代烯基、炔基、卤代炔基、酮基芳基、卤代酮基芳基、酮基杂环芳基、酮基烷基、卤代酮基烷基、酮基烯基、卤代酮基烯基、卤代烷基芳基和卤代烷基杂环芳基的基团，对于适当的基团，一个或多个非相邻的CH2基团可以被—O—、—S—、—NH—、—NR∘∘∘—、—SiR∘R∘∘—、—CO—、—COO—、—COR∘OR∘∘—、—OCO—、—OCO—O—、—SO2-、—S—CO—、—CO—S—、—O—CS—、—CS—O—、—CY1=CY2或—C≡C—中的一个或多个代替，且使O和/或S原子不直接结合，可选地用含有1至30个C原子的芳基或杂环芳基替换（末端CH3基团在CH2-H的意义上被理解为CH2基团）。该发明还涉及在电荷生成层中使用锌络合物作为p-掺杂剂。
• PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme

  公开号：US20150112067A1

  公开（公告）日：2015-04-23

  The disclosure encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, having less steps and improved yields as compared to previous synthetic methods for making these compounds, which are CGRP receptor antagonists, useful for the treatment of migraine. Conditions for an amide bond formation between an acid and amine include for example reacting the compounds of Formulae B (after salt break) and C with an amide coupling reagent and optionally an additive and an acid and/or a base in a non-reactive solvent.

  该披露涵盖了一种制备哌啶酮羧酰胺吲哚和氮杂吲哚衍生物的新工艺，与以前用于制备这些化合物的合成方法相比，该工艺步骤更少且产率更高，这些化合物是CGRP受体拮抗剂，可用于治疗偏头痛。酰胺键形成的条件包括例如将公式B（盐断后）和C的化合物与酰胺偶联试剂以及非反应性溶剂中的可选添加剂和酸和/或碱反应。
• CHEMICAL COMPOUNDS
  申请人：Axten Jeffrey Michael

  公开号：US20120077828A1

  公开（公告）日：2012-03-29

  The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R 1 , R 2 , and R 3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的吲哚啉衍生物。具体而言，本发明涉及按式I所示的化合物：其中R1、R2和R3在此定义。本发明的化合物是PERK的抑制剂，可用于治疗癌症、眼部疾病和与激活的未折叠蛋白质应答途径相关的疾病，如阿尔茨海默病、中风、1型糖尿病帕金森病、亨廷顿病、肌萎缩性侧索硬化、心肌梗死、心血管疾病、动脉硬化和心律失常，更具体地，乳腺癌、结肠癌、胰腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物抑制PERK活性和治疗相关疾病的方法。